Does Farxiga (dapagliflozin) need to be stopped before elective surgery, and if so, how long should it be held?

Yes, Farxiga (dapagliflozin) must be stopped at least 3 days before elective surgery.

Timing of Discontinuation

Farxiga should be withheld for at least 3 days prior to major surgery or procedures associated with prolonged fasting 1. This is the FDA-mandated recommendation based on the drug's pharmacokinetics and the risk of perioperative metabolic acidosis, specifically euglycemic diabetic ketoacidosis (DKA).

Specific Timing by Drug Formulation:

• Dapagliflozin (Farxiga): Stop ≥3 days before surgery 2, 1
• For context with other SGLT2 inhibitors:
  • Canagliflozin and empagliflozin: ≥3 days
  • Ertugliflozin: ≥4 days 2

Why This Matters: The Risk of Euglycemic DKA

The primary concern is euglycemic diabetic ketoacidosis—a life-threatening metabolic acidosis that can occur with normal or near-normal blood glucose levels (often <250 mg/dL, sometimes even <140 mg/dL) 1. This makes it particularly dangerous because:

• Traditional glucose monitoring won't detect the problem
• Surgical stress, fasting, and volume depletion are major precipitating factors 1, 3
• The condition can be fatal if unrecognized 1

The incidence of perioperative DKA is significantly higher in patients taking SGLT2 inhibitors (1.02 vs 0.69 per 1000 patients; OR 1.48) 4. Studies show that holding the drug >2 days preoperatively substantially reduces this risk 4.

Clinical Algorithm for Perioperative Management

Preoperative Phase:

1. Stop dapagliflozin at least 3 days (72 hours) before surgery 1

   • Count backward from the morning of surgery
   • If morning surgery: last dose should be ≥3 days prior
   • If afternoon surgery: provides additional safety margin (>76 hours)

2. Assess and document:

   • Renal function (eGFR) 1
   • Volume status—correct any depletion before surgery 1
   • Diabetes control and insulin requirements
   • Other diabetes medications that may need adjustment

3. Patient counseling:

   • Explain the risk of ketoacidosis
   • Emphasize importance of maintaining hydration
   • Avoid prolonged fasting when possible
   • Monitor for symptoms: nausea, vomiting, abdominal pain, shortness of breath 1

Intraoperative Considerations:

• Maintain adequate hydration with IV fluids
• Consider glucose-containing fluids to mitigate ketone generation during prolonged fasting 4
• Monitor for metabolic acidosis if arterial blood gas obtained

Postoperative Phase:

Resume dapagliflozin only when ALL of the following criteria are met 4, 1:

1. Patient is clinically stable
2. Eating and drinking normally
3. No signs of volume depletion
4. Capillary ketones <0.6 mmol/L (if measured) 4
5. Typically 24-48 hours after low-bleeding-risk surgery
6. May require 48-72 hours or longer after high-bleeding-risk surgery

Monitor for ketoacidosis even after resumption, as cases have been reported up to 2 weeks after SGLT2 inhibitor discontinuation 1.

Critical Pitfalls to Avoid

1. Assuming 1-2 Days is Sufficient

Early recommendations suggested 1-2 days, but this is inadequate. The FDA specifically updated guidance to ≥3 days based on accumulating evidence of perioperative DKA 2, 1. Case series demonstrate DKA occurring even when held for 54-80 hours 3.

2. Relying on Blood Glucose Alone

Euglycemic DKA presents with normal or minimally elevated glucose 1, 3. You must:

• Check ketones (serum or urine) if metabolic acidosis is present
• Look for anion gap metabolic acidosis (pH <7.3, anion gap >12 mmol/L)
• Recognize symptoms: nausea, vomiting, abdominal pain, tachypnea, malaise 1, 3

3. Emergency Surgery Scenarios

For urgent/emergent surgery where 3-day hold is impossible 5:

• Document time since last dose
• Maintain high index of suspicion for DKA
• Consider ketone monitoring perioperatively
• Ensure aggressive hydration
• The incidence of euDKA is 6.5-fold higher in emergency vs elective surgery (1.1% vs 0.17%) 5

4. Special Populations Requiring Extra Caution

Hold for LONGER than 3 days or use extra vigilance in:

• Severe renal impairment (CrCl <30 mL/min): prolonged drug clearance 6
• Patients on insulin: higher DKA risk 4, 3
• Type 1 diabetes: although dapagliflozin isn't indicated, if prescribed off-label, risk is substantially elevated 1
• Recent pancreatitis or pancreatic surgery: additional DKA risk factors 1
• Prolonged fasting expected: cardiac surgery, major abdominal procedures 3, 7

Comparison with Other Perioperative Medication Management

For context, this 3-day hold is longer than most anticoagulants:

• DOACs (apixaban, rivaroxaban): 1-2 days for low-moderate bleed risk 8
• Dabigatran: 1-4 days depending on renal function 8
• Antiplatelet agents: 3-7 days 8

The extended hold for SGLT2 inhibitors reflects the unique and serious risk of euglycemic DKA, not bleeding complications.

When to Consider Continuing (Rare Exceptions)

The only scenario where continuing might be considered is in patients with severe heart failure where acute decompensation risk from stopping outweighs surgical risks 2. However, even the 2024 AHA/ACC guidelines state SGLT2 inhibitors "should be withheld for 3 to 4 days before surgery when feasible" 2. This is a Class 1 recommendation (should be done).

Treatment if Euglycemic DKA Occurs

If suspected postoperatively 1:

1. Stop dapagliflozin immediately
2. Check serum/urine ketones, arterial blood gas, anion gap
3. Initiate insulin infusion (even with normal glucose)
4. Administer dextrose-containing IV fluids
5. Correct volume depletion and electrolyte abnormalities
6. Monitor until ketoacidosis resolves before considering restart

Bottom line: The 3-day preoperative hold is non-negotiable for elective surgery. The risk of fatal euglycemic DKA far outweighs any benefit from continuing the medication through the perioperative period.